Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030005/S250

VALITUDE (Model U125) VALITUDE X4 (Model U128) VISIONIST (Models U225, U226) VISIONIST X4 (Model U228) Firmware Vers

Guidant Corp. · Decision date Dec 19, 2025

FDA DECISIONP030005/S250

What did the FDA approve?

FDA records P030005/S250 as a supplement to PMA P030005, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 19, 2025.

FDA approval order statement

approval for the Software Maintenance Release 6 (SMR6) package of software updates for the ACCOLADE family of pacemakers and CRT-Ps
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Dec 19, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P030005/S250
Regulatory pathway
PMA supplement
Applicant
Guidant Corp.
Product code
NKE
Decision code
APPR
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).

Applicant
Guidant Corp.
Product code
NKE
FDA device class
3

For the original device and its historical approval scope, see PMA P030005. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030005 · Original PMA

    CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE

  2. P030005/S248 · Related supplement

    Accolade Cardiac Resynchronization Therapy Pacemakers, VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Model

  3. P030005/S249 · Related supplement

    U125 VALITUDE CRT-P,U128 VALITUDE X4 CRT-P,U225 VISIONIST CRT-P,U226 VISIONIST CRT-P,U228 VISIONIST X4 CRT-P

  4. P030005/S250 received

    Application receipt date recorded by FDA.

  5. P030005/S251 · Related supplement

    VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)

  6. P030005/S250 · FDA decision

    Real-Time Process

  7. P030005/S247 · Related supplement

    Accolade CRT Pacemakers (CRT-Ps): VALITUDE CRT-P U125; VALITUDE X4 CRT-P Model U128; VISIONIST CRT-P Models U225, U226

  8. P030005/S252 · Related supplement

    CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE

  9. P030005/S254 · Related supplement

    VALITUDE, VALITUDE X4, VISIONIST, VISIONIST X4

  10. P030005/S253 · Related supplement

    INVIVE, INTUA, VISIONIST, VALITUDE

  11. P030005/S255 · Related supplement

    VALITUDE CRT-P IS1 EL (U125); VALITUDE CRT-P IS4 EL (U128); VISIONIST CRT-P IS1 EL (U225); VISIONIST CRT-P LV1 EL (U

  12. P030005/S257 · Related supplement

    VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)

Timeline entries are records held by MedtechLedger for P030005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030005

Product / regulatory recordCompanyPathwayDecision dateSource
Guidant Corp.PMA approvalJan 26, 2004FDA
Guidant Corp.PMA supplementSep 22, 2025FDA
Guidant Corp.PMA supplementOct 22, 2025FDA
Guidant Corp.PMA supplementDec 17, 2025FDA
Guidant Corp.PMA supplementJan 8, 2026FDA
Guidant Corp.PMA supplementApr 1, 2026FDA
Guidant Corp.PMA supplementJun 3, 2026FDA
Guidant Corp.PMA supplementJul 1, 2026FDA
Guidant Corp.PMA supplementJul 23, 2026FDA
Guidant Corp.PMA supplementOct 3, 2026FDA

Explore the linked device profile

Other records with product code NKE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guidant Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records